End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia

Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box warnings advised of early death and venous thrombo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoque, Shamia, Chen, Brian J., Schoen, Martin W., Carson, Kenneth R., Keller, Jesse, Witherspoon, Bartlett J., Knopf, Kevin B., Yang, Y. Tony, Schooley, Benjamin, Nabhan, Chadi, Sartor, Oliver, Yarnold, Paul R., Ray, Paul, Bobolts, Laura, Hrushesky, William J., Dickson, Michael, Bennett, Charles L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316310/
https://www.ncbi.nlm.nih.gov/pubmed/32584835
http://dx.doi.org/10.1371/journal.pone.0234541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316310/
https://www.ncbi.nlm.nih.gov/pubmed/32584835
http://dx.doi.org/10.1371/journal.pone.0234541

Ejemplares similares